Weekly Gemcitabine and Trastuzumab in the Treatment of Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Metastatic Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Trastuzumab|DRUG: Gemcitabine
Sponsor: SCRI Development Innovations, LLC
Collaborators: Eli Lilly and Company|Genentech, Inc.